SCHEMBL3177993

SCHEMBL3177993

CCCOCNC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.46
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
GAA P10253 1/20 0.43
CA1 P00915 5/20 0.42
CA12 O43570 4/20 0.42
CA7 P43166 2/20 0.42
CA14 Q9ULX7 1/20 0.42
CA2 P00918 4/20 0.41
CA9 Q16790 3/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
CTSK P43235 4/20 0.40
CTSS P25774 3/20 0.40
EPHX1 P07099 1/20 0.38
ALDH1A1 P00352 2/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10072751 0.85 TDP1 (0.51) TDP1KMT2AMEN1GAACA1
SCHEMBL16923544 0.84 TDP1 (0.55) TDP1KMT2AMEN1GAACA1
SCHEMBL26315916 0.83 TDP1 (0.50) TDP1KMT2AMEN1GAACA1
SCHEMBL47067 0.83 TDP1 (0.50) TDP1KMT2AMEN1GAACA1
SCHEMBL22862014 0.83 TDP1 (0.50) TDP1KMT2AMEN1GAACA1
SCHEMBL14258531 0.83 TDP1 (0.50) TDP1KMT2AMEN1GAACA1
SCHEMBL18365026 0.83 TDP1 (0.50) TDP1KMT2AMEN1GAACA1
SCHEMBL18591853 0.83 TDP1 (0.50) TDP1KMT2AMEN1GAACA1
SCHEMBL16923542 0.82 TDP1 (0.44) TDP1KMT2AMEN1GAACA1
SCHEMBL8983076 0.82 TDP1 (0.44) TDP1KMT2AMEN1GAACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100022515-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-28 US claimed
EP-2114890-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-11-11 EP claimed
WO-2008097428-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2008-08-14 WO claimed
US-20100022515-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-28 US disclosed
EP-2114890-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2009-11-11 EP disclosed
WO-2008097428-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022515-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GCGR, GPR65 TDP1 4755/4885KMT2A 3065/4885MEN1 3608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.